DALLAS--(BUSINESS WIRE)--Baron and Budd, a national law firm dedicated to protecting the rights of mesothelioma patients, has underwritten the printing and distribution of updated NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma. Made possible by the generous support of the mesothelioma lawyers at Baron and Budd, these new guidelines are a translation of the latest version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
“As a firm dedicated to mesothelioma patients, we wanted to help bring valuable information to patients suffering from this horrible cancer. We are proud to partner with NCCN on the translation of these updated guidelines.”
The NCCN Guidelines® are created by multidisciplinary panels of cancer experts from NCCN Member Institutions and feature algorithms or “decision trees” that address every appropriate management option from initial work-up throughout the course of the disease. The updated NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma translate the latest version of NCCN Guidelines® for Malignant Pleural Mesothelioma into an understandable resource for patients and caregivers. The updated NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma give patients access to information about the most recent advancements in mesothelioma treatment to help them make informed decisions about their care.
“Since mesothelioma is only diagnosed in approximately 3,000 people each year, it can be difficult for patients to find quality resources about treatment,” said Russell Budd, founder and managing shareholder of Baron and Budd and representative to the NCCN Foundation Board of Directors. “As a firm dedicated to mesothelioma patients, we wanted to help bring valuable information to patients suffering from this horrible cancer. We are proud to partner with NCCN on the translation of these updated guidelines.”
Baron and Budd was one of the first law firms to successfully handle a mesothelioma lawsuit in the United States and is proud to continue fighting on behalf of mesothelioma patients 35 years later. Under the leadership of firm founder Russell Budd, Baron and Budd has contributed to numerous non-profit organizations to help advocate for asbestos victims and find a cure for mesothelioma. Budd is the only attorney who holds a seat on the Board of Directors of the NCCN Foundation. The firm was an inaugural donor to the International Mesothelioma Program (IMP) at Brigham and Women’s in Boston and a 2012 and 2013 Platinum-level sponsor of the Asbestos Disease Awareness Organization (ADAO). Baron and Budd also previously underwrote the book Understanding Mesothelioma from CURE Media Group.
For a complimentary printed copy of the updated NCCN Guidelines for Patients®: Malignant Pleural Mesothelioma, call 1.866.855.1229 or email firstname.lastname@example.org.
About Baron & Budd, P.C.
The national mesothelioma law firm of Baron & Budd, P.C. has been “Protecting What’s Right” for asbestos sufferers and their families for nearly 40 years. As one of the first law firms to successfully litigate an asbestos lawsuit, Baron & Budd continues to actively represent veterans, industry workers and others who are suffering as a result of exposure to asbestos. Contact Baron and Budd at 1.866.855.1229 for additional information on mesothelioma treatments, mesothelioma cancer doctors and treatment centers and mesothelioma attorneys.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas MD Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.